Major considerations and updates in immunotherapy for advanced prostate cancer

“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.

In this video, Susan F. Slovin, MD, PhD, discusses takeaways of her presentation on immunotherapy in advanced prostate cancer, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, and upcoming research. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.